The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Teva to divest remaining women's health assets for $1.38bn.....           Roche says Venetoclax combination improves PFS in phase III CLL trial.....           Ultragenyx proposes to acquire Dimension Therapeutics.....           FDA grants orphan drug status for Motif Bio?s Staphylococcus Aureus lung treatment.....           Teva finishes women's health sale with deals worth $1.38B.....           Fosun, said to be stymied by India's buyout rules, now aims for smaller Gland Pharma stake in $1.1B deal.....           Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients.....           FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths.....           J&J, BARDA partner up to advance pandemic flu preparedness.....           Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies.....           Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar Cyltezo.....           CHMP recommends GSK, Innoviva?s single inhaler triple therapy for COPD.....           Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds.....           Bayer gears up to take on Gilead in lymphoma with Aliqopa green light.....           Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds.....           FiercePharmaAsia?NextCODE?s $240M financing, Celltrion?s Inflectra plant, Biocon?s insulin plant.....           Samsung wins first CHMP backing for a Herceptin biosim, imperiling $2B in Roche sales.....           Cash-strapped Teva closes in on women's health sale No. 2: report.....           Tesaro earns CHMP thumbs-up for Zejula as three-way PARP race heats up.....           FDA approves biosimilar of Avastin to treat five types of cancer.....           BMS to use Halozyme?s Enhanze technology to develop immuno-oncology medicines.....           Vanda's tradipitant improves itch and disease severity in patients with atopic dermatitis.....           Bydureon EXSCEL trial shows favorable cardiovascular safety profile in patients with type-2 diabetes.....           Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds.....           EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study.....           EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study.....           Xtandi's new Prosper trial win has Pfizer and Astellas eyeing a bigger market.....           California lawmakers pass drug pricing bill opposed by PhRMA, sending it to the governor.....           Shkreli said he wouldn?t go to jail, but then he posted about Clinton?s hair.....           Why did AstraZeneca's Bydureon fail to cut CV risks? A broad patient group, perhaps.....           Amicus Therapeutics? skin disorder drug SD-101 fails in phase 3 trial.....           FDA advisory panel recommends approval of GSK?s shingles vaccine Shingrix.....           Inotek Pharmaceuticals announces merger deal with Rocket Pharmaceuticals.....           Berkeley Lights, Bayer partner for cell line development and antibody discovery.....           EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study.....           EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show.....           EASD: Novo Nordisk's combo Xultophy beat rivals at cutting LDL, blood pressure.....           Almirall launches new corporate ID to align with dermatology and aesthetic focus.....           EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show.....           Hemo-oncology newbie Bayer gears up for copanlisib launch.....           Mylan blasts Allergan's 'desperate' tribal licensing deal on Restasis.....           ESMO: Pfizer boosts Ibrance's class with positive neutropenia data.....           Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis.....           EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point.....           FDA panel unanimously endorses Glaxo's Shingrix as $1B market duel nears.....           Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI.....           AstraZeneca?s Imfinzi lung cancer drug shows significant effect in PACIFIC trial.....           Onxeo?s liver cancer drug Livatag fails in phase 3 trial.....           FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports.....           Alexion plots hundreds of layoffs, HQ move in sweeping corporate revamp.....           Teva lures Lundbeck chief Schultz with $52M package that makes him among pharma's top paid.....           Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates.....           Janssen scraps hepatitis C development program.....           Janssen scraps hepatitis C development program.....           HitGen, Takeda enter DNA-encoded library based drug discovery research collaboration.....           HitGen, Takeda enter DNA-encoded library based drug discovery research collaboration.....           IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results.....           IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results.....           Cancer patients know immuno-oncology and top drugs, but lack details: study.....           ESMO need-to-know: Keytruda misses head and neck; Tagrisso wins; plus Lilly, BMS and more.....           ESMO: Merck details Keytruda's narrow head and neck cancer miss in phase 3.....           Boehringer Ingelheim, Gubra to develop next generation obesity treatments.....           Boehringer Ingelheim, Gubra to develop next generation obesity treatments.....           Teva finally nabs a CEO, and it's Lundbeck helmsman?and Novo ex?Kåre Schultz.....           Allergan, author of the 'social contract,' stirs up hornet's nest with controversial IP deal.....           ESMO need-to-know: Keytruda misses head and neck; Tagrisso wins; plus Lilly, BMS and more.....           Teva makes good on asset-sale vows with $1.1B contraceptive sale.....           Regeneron, Sanofi get FDA breakthrough therapy status for skin cancer drug cemiplimab.....           Regeneron, Sanofi get FDA breakthrough therapy status for skin cancer drug cemiplimab.....           European Investment Bank grants €75m funding for Evotec.....           European Investment Bank grants €75m funding for Evotec.....           Teva?s migraine drug fremanezumab succeeds in phase 3 studies.....           Teva?s migraine drug fremanezumab succeeds in phase 3 studies.....           Teva finally nabs a CEO, and it's Lundbeck helmsman?and Novo ex?Kåre Schultz.....           With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
PharmSci 2017 - first announcement

Tuesday 5 - Thursday 7 September 2017 at De Havilland Campus, University of Hertfordshire, Hatfield

The theme of the conference in 2017 is:
'Pharmaceutical Science without Borders'

The APS is pleased to announce Professor Abdul Basit as this year's Conference Science Chair.

Professor of Pharmaceutics at the School of Pharmacy, University College London, where he leads a research group investigating drug delivery to the gastrointestinal tract.

"I am delighted to be Chairing the 8th APS International PharmSci Conference 2017 at the University of Hertfordshire, where our focus this year is "Pharmaceutical Science without Borders". Pharmaceutical science transcends a multitude of borders - it is very much an international field, collaborative in nature and underpins medicines development. The healthcare challenges we face today are global, and cannot be addressed in isolation. Our aim in this conference is to connect, empower and inspire those of you across the pharmaceutical sciences sector and beyond; to broaden your research goals and horizons alongside showcasing pragmatic approaches to trouble-shooting/problem-solving in the pharmaceutical sciences. I look forward to welcoming you to what will no doubt be a fascinating and intellectually stimulating event."

You can become part of this conference now.

Reserve the date, suggest a topic, offer a poster presentation, reserve an exhibition space and many other opportunities. Please email info@apsgb.org.

Please also regularly check the PharmSci website for updates.
 

PharmSci 2016 Conference - Chair's review

The Chair of the Academy of Phamaceutical Sciences, Dr Linda Hakes, gives a brief review of the 7th APS International PharmSci Conference, held in Glasgow on 5-7 September 2016.

"2016 has come to an end and although I admit that I am probably biased, I think it was a fantastic three days. The venue, the Technology and Innovation Centre at Strathclyde University, was well equipped to handle the conference and the facilities are modern and efficient.

All of the conference sessions (as far as I could tell) were well attended and the plenary lectures were all excellent, covering topics ranging across the spectrum of pharmaceutical sciences, embracing chemistry, pharmacology, medical devices, formulation, pharmacokinetics and spectroscopy.

A highlight of the social side was the Civic Reception in the City Chambers, a magnificent building on George Square, where we were warmly welcomed by the Bailey Steward on behalf of the Lord Provost of Glasgow.

 

 

 

 

 

As always the Black Tie Dinner was a great success and we were pleased to have Prof. Sandy Florence as guest speaker. Again, the venue was truly impressive – the Barony Hall.

 

 

 

 


To sum up, I believe we enjoyed a conference full of good science, excellent networking opportunities, and highly enjoyable social events. If you weren’t there, why not make a note for next year –
Tuesday 5 - Thursday 7 September 2017 at the University of
Hertfordshire .

See you there!"

Latest News
RPS Excellence in Pharmaceutical Science Excellence in Pharmaceutical Science Award
WEDNESDAY, 10 MAY 2017
Excellence in Pharmaceutical Science recognises those who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science. . The nominee should have demonstrated excellence in pharmaceutical science, by showing innovation and initiative, and contributing to a project which has had an impact on the improvement of pharmaceutical science.. To download the nomination form, please visit us online here:. https://www.rpharms.com/events/rps-awards. To be considered for the nomination the nominee must cover all aspects in the criteria. Completed nomination forms should be sent to events@rpharms.com by Monday 29 May 5pm..
Applications invited for the 2017 Royal Pharmaceutical Society Science Award
TUESDAY, 9 MAY 2017
Applications are invited for the 2017 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the Academy of Pharmaceutical Sciences International PharmSci Conference meeting on Thursday 7th September 2017.. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2017, applicants must have a proven record of independent research and published work that shows outstanding promise. . Applicants are invited to submit the following details by 31st May 2017: . · Full CV detailing personal information, past and present appointments, research responsibilities and published work. . · List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations . · Details of research grants awarded and the candidate’s role . · Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards . · A brief resume of two pages should also be submitted with the CV, indicating discoveries made (please note copies of publications are not required). . Submissions should be sent to: evidence@rpharms.com or by post to: Rachel Joynes, Head of Research Royal Pharmaceutical Society 66-68 East Smithfield London E1W 1AW. .
APS 8th International PharmSci Conference 2017 Call for Abstracts
THURSDAY, 12 JANUARY 2017
. 'Pharmaceutical Sciences Without Borders’. Tuesday 5 – Thursday 7 September 2017 De Havilland Campus of the University of Hertfordshire in Hatfield. Call for Abstracts. Abstracts are invited for posters for APS International PharmSci 2017. This is one of the most exciting parts of the conference as it represents the presentation of the very latest pharmaceutical science research.. Abstracts on any aspect of the Pharmaceutical Sciences are welcomed and those with a particular emphasis on the theme of this year’s Conference, 'Pharmaceutical Sciences Without Borders’ are particularly appreciated. Details of the various subject categories, an abstract template and details of the entry process can be found here:. http://www.ukpharmsci.org/abstracts/default.asp. Please ensure abstracts are submitted online and comply with the Abstract Submission Template. Please note one or two page abstracts are welcomed providing they follow the template.. There will be prizes awarded for winning posters on each day of the Conference and authors of abstracts of particular interest will be invited to give podium presentations (15min). This is an excellent chance to get your science recognised at the UK’s premier Pharmaceutical Science Conference. The closing date for abstract submission is Friday 17th March 2017.. Abstracts will be made available to Conference registrants when the abstract author has registered for the Conference. We also intend to publish the abstracts in a journal after the Conference and authors not wishing to take up this opportunity are requested to indicate this where indicated when they submit their abstract.. Entrants in the Analytical Chemistry category may be eligible for the Geoffrey Phillips Analytical Science Award, subject to meeting the criteria, awarded by the Joint Pharmaceutical Analysis Group (JPAG). The purpose of the Award is to encourage the advancement of pharmaceutical analysis and to recognise contributions of emerging scientists reporting wholly or mainly their own work. The winner receives a prestigious award with a bursary of up to £1000 to attend a conference relevant to their area of interest.. http://www.jpag.org/?&sid=20170112135948802597&p=awards#award. Exhibitor Opportunities. The conference includes a large pharmaceutical sciences exhibition, which is open to large pharma companies, small and medium size enterprises (SMEs), contract research organisations (CROs) and technology suppliers. With one of the largest gatherings of pharmaceutical scientists in the UK, the conference offers a great opportunity to showcase your company.. For more information please contact us: info@apsgb.org or 0116 274 7351. .
APS Fellowships Announcement 2017
WEDNESDAY, 2 NOVEMBER 2016
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to info@apsgb.org by 1 March 2017.

Follow us
 
Upcoming Events
APS Advances in Amorphous Design, Control and Delivery of Amorphous and Co-amorphous Pharmaceutical Materials
3 October 2017
MIBio 2017: Stability of Biopharmaceuticals – From Molecular Interactions to Successful Products
4 October 2017
APS Developing Clinically Relevant Dissolution Specifications for Oral Drug Products - Industrial and Regulatory Perspectives
APS Biopharmaceutics and Regulatory Sciences Joint Meeting

7 November 2017
Pharma Integrates 2017
15 - 16 November 2017
Antimicrobial Resistance: Novel Therapeutics and Drug Discovery
Joint meeting with the Society for Applied Microbiology

23 November 2017
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.